Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer

Journal of Clinical Oncology

Volumn 24, Issue 24, 2006, Pages 3919-3926

  Kröger, Nicolaus ^a   Frick, Markus ^b   Gluz, Oleg ^b   Mohrmann, Svjetlana ^b   Metzner, Bernd ^b   Jackisch, Christian ^b   Ko, Yon ^b   Lindemann, Hans Walter ^b   Meier, Carl Richard ^b   Lohrmann, Hans Peter ^b   Ruffert, Ute ^b   Hänel, Matthias ^b   Bodenstein, Heinrich ^b   Neubauer, Andreas ^b   Ehninger, Gerhard ^b   Wolf, Hans Heinrich ^b   Kolbe, Kathrin ^b   Burock, Karin ^b   Zander, Axel R ^b   Nitz, Ulrike ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ADJUVANT THERAPY; ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DYSPNEA; FEMALE; HEART ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEM CELL MOBILIZATION; TREATMENT RESPONSE; VOMITING; AUTOTRANSPLANTATION; BREAST TUMOR; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; PATHOLOGY; RISK; SURVIVAL; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; SURVIVAL ANALYSIS; THIOTEPA; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 33748445360     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.04.0352     Document Type: Article

References (25)

1. Clark GM, Sledge GW Jr, Osborne CK, et al: Survival from first recurrence: Relative importance of prognostic factors in 1015 breast cancer patients. J Clin Oncol 5:55-61, 1987
2. Hortobagyi GN, Frye D, Buzdar AU, et al: Complete remission in metastatic breast cancer: A thirteen year follow-up report. Proc Am Soc Clin Oncol 7:143, 1988 (abstr)
3. Williams SF, Gilewski T, Mick R, et al: High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: Follow-up report. J Clin Oncol 10:1743-1747, 1992
4. Antman K, Ayash L, Elias A, et al: A phase II study of high-dose cyclophosphamide, thiotepa and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard dose therapy. J Clin Oncol 10:102-110, 1992
5. Peters WP: Five year follow-up of high-dose combination alkylating agents with ABMT as consolidation after standard-dose CAF for primary breast cancer involving >10 axillary lymph nodes (Duke/CALBGI 8782). Proc Am Soc Clin Oncol 14:317, 1995 (abstr 933)
6. Dunphy FR, Spitzer G, Buzdar AU, et al: Treatment of estrogen receptor negative or hormonally refractory breast cancer with double dose chemotherapy intensification and bone marrow support. J Clin Oncol 8:1207-1216, 1990
7. Broun ER, Sridhara R, Sledge W, et al: Tandem autotransplantation for the treatment of metastatic breast cancer. J Clin Oncol 13:2050-2055, 1995
8. Bitran J, Samuels B, Klein L, et al: Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage in stage IV breast cancer. Bone Marrow Transplant 17:157-162, 1996
9. Ayash LJ, Elias A, Schwartz G, et al: Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: No improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. J Clin Oncol 14:2984-2992, 1996
10. Peto R, Peto J: Asymptotically efficient rank invariation test procedures (with discussion). J R Stat Soc A 135:185-206, 1972
11. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
12. Hryniuk W, Levine MN: Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4:1162-1170, 1986
13. Peters WP, Shpall EJ, Jones RB, et al: High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6:1368-1376, 1988
14. Kennedy MJ, Beveridge RA, Rowley SD, et al: High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 83:920-926, 1991
15. Stadtmauer EA, O'Neill L, Goldstein LJ, et al: Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer: Philadelphia Bone Marrow Transplant Group. N Engl J Med 342:1069-1076, 2000
16. Crump M, Gluck S, Stewart D, et al: A randomized trial of high-dose chemotherapy (HDC) with autologous peripheral blood stem cell support (AHPCT) compared to standard chemotherapy in women with metastatic breast cancer: A National Cancer Institute of Canada (NCIC) Clinical Trials Group study. Proc Am Soc Clin Oncol 20:21a, 2001 (abstr 82)
17. Lotz JP, Curé H, Janvier M, et al: Intensive chemotherapy and autograft of hematopoietic stem cells in the treatment of metastatic cancer: Results of the national protocol PEGASE 04. Hematol Cell Ther 41:71-74, 1999
18. Peters WP, Jones RB, Vredenburgh J, et al: A large, prospective, randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (ARM). Proc Am Soc Clin Oncol 15:121, 1996 (abstr 149)
19. Berry DA, Broadwater G, Klein JP, et al: High-dose versus standard chemotherapy in metastatic breast cancer: Comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 20:743-750, 2002
20. Schmid P, Schippinger W, Nitsch T, et al: Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: Results of a randomized trial. J Clin Oncol 23:432-440, 2005
21. Crown J, Perey L, Lind M, et al: Superiority of tandem high-dose chemotherapy (HDC) versus optimized conventionally-dosed chemotherapy (CDC) in patients (pts) with metastatic breast cancer (MBC): The International Randomized Breast Cancer Dose Intensity Study (IBDIS 1). Proc Am Soc Clin Oncol 22:23, 2003 (abstr 88)
22. Biron P, Durand M, Roché H, et al: High dose thiotepa (TTP), cyclophosphamide (CPM) and stem cell transplantation after 4 FEC 100 compared with 4 FEC alone allowed a better disease free survival but the same overall survival in first line chemotherapy for metastatic breast cancer: Results of the PEGASE 03 French Protocol. Proc Am Soc Clin Oncol 21:42a, 2002 (abstr 167)
23. Madan B, Broadwater G, Ruin P, et al: Improved survival with consolidation high-dose cyclophosphamide, cisplatin and carmustine (Hd-Cpb) compared with observation in women with metastatic breast cancer (Mbc) and only bone metastases treated with induction Adriamycin, 5-fluorouracil and methotrexate. Proc Am Soc Clin Oncol 19:48a, 2000 (abstr 184)
24. Nieto Y, Nawaz S, Jones RB, et al: Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol 20:707-718, 2002
25. Rowlings PA, Williams SF, Antman KH, et al: Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. JAMA 282:1335-1343, 1999